Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avapritinib

FDA-approved product (tablet, oral), marketed as Ayvakit.

Registered studies
30
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Avapritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gastrointestinal stromal tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avapritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avapritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

    NCT04773782 · start 2022-02-24

    Registered record
    Registry ID
    NCT04773782
    Conditions
    Solid Tumor, Unspecified, Child; Relapsed Solid Neoplasm; CNS Tumor
    Interventions
    avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-02-24
    Completion
    2025-11-21
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Unspecified, Child; Relapsed Solid Neoplasm; CNS Tumor
    Interventionavapritinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study for Patients Previously Treated in Avapritinib Clinical Trials

    NCT04825574 · start 2021-05-21

    Registered record
    Registry ID
    NCT04825574
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-21
    Completion
    2023-11-23
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionAvapritinib
    PhasePhase 4
    Registry statusCompleted

  • French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients

    NCT04927260 · start 2021-03-31

    Registered record
    Registry ID
    NCT04927260
    Conditions
    GIST; GIST, Malignant; PDGFR-Alpha D842V
    Interventions
    Patient treated by Avapritinib in real life
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-03-31
    Completion
    2024-12-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST; GIST, Malignant; PDGFR-Alpha D842V
    InterventionPatient treated by Avapritinib in real life
    PhaseNot recorded
    Registry statusUnknown

  • Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

    NCT04771520 · start 2021-01-20

    Registered record
    Registry ID
    NCT04771520
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Locally Advanced Primary Malignant Central Nervous System Neoplasm; Locally Advanced Sarcoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Primary Malignant Central Nervous System Neoplasm; Metastatic Sarcoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarci
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-01-20
    Completion
    2026-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 +14 more
    InterventionAvapritinib
    PhasePhase 2
    Registry statusRecruiting

  • Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

    NCT04695431 · start 2020-12-02

    Registered record
    Registry ID
    NCT04695431
    Conditions
    Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematological Neoplasm; Mast Cell Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-02
    Completion
    2021-10-04
    Enrolment
    317

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematological Neoplasm; Mast Cell Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

    NCT04116541 · start 2020-01-28

    Registered record
    Registry ID
    NCT04116541
    Conditions
    Malignant Solid Tumor
    Interventions
    HDM201; Ribociclib; Cabozantinib; Alectinib; Regorafenib; Trametinib; Dabrafenib; Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-01-28
    Completion
    2027-10
    Enrolment
    455

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Tumor
    InterventionHDM201; Ribociclib; Cabozantinib; Alectinib +4 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

    NCT04254939 · start 2019-08-15

    Registered record
    Registry ID
    NCT04254939
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    CS3007 (BLU-285)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-08-15
    Completion
    2023-04-11
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionCS3007 (BLU-285)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

    NCT03731260 · start 2019-04-16

    Registered record
    Registry ID
    NCT03731260
    Conditions
    Indolent Systemic Mastocytosis
    Interventions
    Avapritinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-16
    Completion
    2027-06-23
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIndolent Systemic Mastocytosis
    InterventionAvapritinib; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

    NCT03580655 · start 2018-11-21

    Registered record
    Registry ID
    NCT03580655
    Conditions
    Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematologic Neoplasm; Mast Cell Leukemia
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-21
    Completion
    2024-12-18
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematologic Neoplasm; Mast Cell Leukemia
    InterventionAvapritinib
    PhasePhase 2
    Registry statusCompleted

  • (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

    NCT03465722 · start 2018-03-26

    Registered record
    Registry ID
    NCT03465722
    Conditions
    GIST
    Interventions
    avapritinib; regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-03-26
    Completion
    2021-09-15
    Enrolment
    476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    Interventionavapritinib; regorafenib
    PhasePhase 3
    Registry statusCompleted

  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

    NCT03056599 · start 2016-12-15

    Registered record
    Registry ID
    NCT03056599
    Conditions
    Soft Tissue Sarcoma Adult
    Interventions
    Multiple drug microinjection; CIVO device
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12-15
    Completion
    2021-09-22
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma Adult
    InterventionMultiple drug microinjection; CIVO device
    PhasePhase 1
    Registry statusCompleted

  • (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

    NCT02561988 · start 2016-03-10

    Registered record
    Registry ID
    NCT02561988
    Conditions
    Aggressive Systemic Mastocytosis; Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease; Mast Cell Leukemia; Relapsed or Refractory Myeloid Malignancies
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03-10
    Completion
    2023-01-19
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAggressive Systemic Mastocytosis; Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease; Mast Cell Leukemia; Relapsed or Refractory Myeloid Malignancies
    InterventionAvapritinib
    PhasePhase 1
    Registry statusCompleted

  • (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

    NCT02508532 · start 2015-08

    Registered record
    Registry ID
    NCT02508532
    Conditions
    Gastrointestinal Stromal Tumors (GIST); Other Relapsed or Refractory Solid Tumors
    Interventions
    Avapritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-08
    Completion
    2021-06-03
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors (GIST); Other Relapsed or Refractory Solid Tumors
    InterventionAvapritinib
    PhasePhase 1
    Registry statusCompleted

  • Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

    NCT03862885

    Registered record
    Registry ID
    NCT03862885
    Conditions
    GIST
    Interventions
    Avapritinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionAvapritinib
    PhaseNot recorded
    Registry statusApproved for marketing

  • Expanded Access Program for Avapritinib

    NCT04714086

    Registered record
    Registry ID
    NCT04714086
    Conditions
    Solid Tumors
    Interventions
    Avapritinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionAvapritinib
    PhaseNot recorded
    Registry statusNo longer available